Novo Nordisk, the Danish maker of insulin, said all of its global manufacturing facilities will run on electricity generated from renewable sources by 2020.
Strides Shasun has resumed limited production at its Cuddalore API plant in India following a fire last week that killed one worker.
South Africa-based Ascendis Health has acquired a 23,000-square-foot manufacturing facility as part of its $24.6 million deal for the pharmaceutical business of Akacia Healthcare.
Pfizer and Allergan are reportedly close to announcing a merger that would turn the two into the largest of the Big Pharma companies, Bloomberg has reported. They also would have the largest manufacturing network with possibly more than 100 production facilities. But Pfizer's acquisition record suggests that number would shrink significantly postmerger as it looked for ways to cut costs to pay for the massive deal.
The hemophilia A treatment Advate is the cornerstone to the future of Baxalta, the company that was created when Baxter International spun off its drug operations in July. Now the newbie will be able to produce more of the product at a plant in Singapore it opened just last year.
Novartis India Managing Director Ranjit Shahani told India's PTI that the drugmaker expects upgrades at two Sandoz plants that were issued a warning letter by the FDA to soon be back to full production.
Roche will close four plants around the world and lay off 1,200 people as it moves to new technology for manufacturing small molecule drugs. It says it will build a late-stage technical development and launch facility in Switzerland for targeted, high-potency drugs.
Cellular Biomedicine, a biotech working in the hot new area of treating cancer by creating CAR-T cells, has opened another facility in China.
For several months, Sanofi's new CEO Olivier Brandicourt has indicated that one part of his turnaround plan for the French drugmaker would involve significant changes in manufacturing to make it more efficient. And while the CEO told investors Friday that he would be looking for $1.6 billion in cost cuts in the next three years, and that some would come from a "reshape" of the manufacturing network, he was short on details about how that might play out.
CDMO Almac is taking over some facilities abandoned by AstraZeneca in the U.K. some years back and will build them out to expand its own formulation and manufacturing operations.